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Abstract
The activity against Gram-positive bacteria of 3,4,5,3′,5′-pentabromo-2-(2′-hydroxybenzoyl)pyrrole I, a synthetic anti-bacterial compound
related to pyrrolomycins, was tested in vitro using seven reference bacterial strains and Staphylococcus epidermidis and Staphylococcus
aureus preformed biofilms. Compound I was active against all strains tested, with minimum inhibitory concentration (MIC) values ranging
from 0.002 to 0.097 mg/l and minimum bactericidal concentrations (MBCs) from 0.37 to 12.5 mg/l. Compound I was also active at low
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. Introduction
Gram-positive bacteria are a significant cause of hospital-
cquired and community infections and may induce diseases
ssociated with serious levels of morbidity and mortality.
oreover, antibiotic resistance of important Gram-positive
athogens, such as Staphylococcus aureus, Streptococcus
neumoniae andEnterococcus faecalis has become one of the
ajor worldwide health problems. The recent appearance in
any countries of vancomycin-intermediate resistant (VISA)
nd vancomycin-resistant S. aureus isolates (VRSA) [1] is the
atest development in antibiotic resistance. Staphylococcal
iofilms play an important role in human pathology because
hey represent an intrinsic form of resistance to antibiotics
nd colonize the surface of indwelling medical devices [2].
Biofilm-forming staphylococci cause infections that are
ery difficult to treat [3], and there is an urgent need to de-
elop new agents to halt these pathogens. One approach is to
mprove the activity of natural anti-microbial substances by
ynthesis of analogous compounds. For this reason, we turned
ur attention to naturally produced organohalogens [4], and
such as pentabromopseudilin and pyoluteorin [5,6], respec-
tively produced by bacteria Pseudoalteromonas luteovio-
laceus and Pseudomonas aeruginosa and pyrrolomycins [7]
produced by some fungi. All these metabolites show good
anti-microbial activity especially against Gram-positive bac-
teria.
We have previously described the synthesis of a series of
bioactive brominated compounds related to monodeoxypy-
oluteorin [8], and we have reported the activity of these com-
pounds against antibiotic sensitive and resistant S. aureus
clinical strains [9].
In this paper, we report new biological activities
of 3,4,5,3′,5′-pentabromo-2-(2′-hydroxybenzoil)pyrrole I,
which was the most active of the brominated compounds
series, against Gram-positive bacteria and as a potential anti-
biofilm agent.
2. Materials and methods
2.1. Synthesis
n particular to the halogenated pyrroles from natural sources,
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3,4,5,3′,5′-Pentabromo-2-(2′-hydroxybenzoil)pyrrole I
(Fig. 1) was synthesized by methods previously described
[8].
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Fig. 1. 3,4,5,3′,5′-Pentabromo-2-(2′-hydroxybenzoil)pyrrole I molecular
structure.
2.2. Microorganisms
The strains used were S. aureus ATCC 25923, S. aureus
ATCC 29213, Staphylococcus epidermidis ATCC 12228,
S. epidermidis DSM 3269, Streptococcus agalactiae ATCC
13813,E. faecalisATCC 29212,Bacillus subtilisATCC 6633
and Listeria monocytogenes NCTC 7973.
2.3. Determination of minimum inhibitory
concentrations (MICs) by broth dilution micro-method
A series of solutions was prepared with a range of con-
centrations from 50 to 0.001 mg/l (obtained by two-fold serial
dilution). The serial dilutions were made in Mueller–Hinton
broth (Merck) in a 96-wells plate, starting from a stock solu-
tion of 5 mg/ml in 1:1 (v/v) DMF/sodium hydroxide 0.1 M.
To each well, 10l of a bacterial suspension from a 24 h cul-
ture containing ∼106 cfu/ml was added [10]. The plate was
incubated at 37 ◦C for 24 h; after this time, the MICs were
determined by a microplate reader (ELX 800, Bio-Tek Instru-
ments) as the lowest concentration of compound whose o.d.,
read at 570 nm, was comparable with the negative control
wells (broth only, without inoculum). Vancomycin was used
for comparative purposes and quality control of the method.


















the medium was removed, the plates were air-dried and then
each well filled with 100l of PBS supplemented with 5l
of a 5 mg/ml MTT (methylthiazotetrazolium) solution and
incubated for 1 h at 37 ◦C. The insoluble purple formazan,
obtained by cleavage of MTT made by dehydrogenase en-
zymes of living cells, was dissolved with a mixture of acidic
isopropyl alcohol and Triton X-100 (Sigma). The o.d. of each
well was read by a microplate reader (ELX 800, Bio-Tek in-
struments) at 570 nm with background subtraction at 630 nm.
Comparison of the absorbance of positive control wells with
absorbance of sample wells enabled the calculation of inhi-
bition percentages of substance I at several concentrations.
2.6. Bioﬁlms susceptibility testing, crystal violet method
S. epidermidis DSM 3269 and S. aureus ATCC 29213
were grown, diluted and wells were washed as previously
described for the MTT method. The plates were air-dried at
37 ◦C and to each well was added 100l of Mueller–Hinton
supplemented with several concentrations, ranging from 1.5
to 0.047g/ml, of substance I, except in the case of positive
controls. The plates were incubated at 37 ◦C for 24 h; after
this incubation time, the medium was removed, the plates
were air-dried and then each well was filled with crystal vio-
let solution (0.1%) for 15–20 min. The plate was then washed

























The minimum bactericidal concentration was obtained by
ubculturing 0.1 ml from each negative well and from the
ositive control of MIC determination, onto substance-free
ueller–Hinton agar plates. The plates were incubated at
7 ◦C for 24 h. The MBC was defined as the lowest concen-
ration of substance, which produced subcultures growing no
ore than three colonies.
.5. Bioﬁlm susceptibility testing,
ethylthiazotetrazolium (MTT) method
S. epidermidisDSM 3269 andS. aureusATCC 29213 were
rown and diluted as described previously [11]. After cultiva-
ion for 24 h at 37 ◦C in 96-well plates, the wells were washed
hree times with 200l of sterile phosphate-buffered saline
PBS). The plates were air-dried at 37 ◦C and to each well was
dded 100l of Mueller–Hinton supplemented with several
oncentrations, ranging from 1.5 to 0.047g/ml, of substance
, except in the case of positive (growth) controls. The plates
ere incubated at 37 ◦C for 24 h; after this incubation time,50–200l of ethanol by pipetting up and down. The plate
as read at 570 nm using a microplate reader. Inhibition per-
entages at several concentrations of substance I were ob-
ained by comparing the o.d. of control wells with that of the
ample wells.
. Results and discussion
.1. Anti-microbial activity
.1.1. MIC, MBC and anti-bioﬁlm results
Compound I was tested for its in vitro anti-bacterial ac-
ivity on a group of Gram-positive bacteria.
The anti-bacterial activities of compound I, expressed as
inimum inhibitory concentration and minimum bactericidal
oncentration, are shown in Table 1 along with the activity
f vancomycin for comparison. Compound I was found to
e active against all strains tested with MIC values ranging
rom 0.002 to 0.097 mg/l and MBCs ranging from 0.37 to
2.5 mg/l.
Compound I showed considerable activity against a
iofilm-positive strain of S. epidermidis DSM 3269, with
nhibition percentages ranging from 100 to 49.4% or 82
o 46.5% at concentrations ranging from 1.5 to 0.047 mg/l
Fig. 2) using, respectively, MTT or crystal violet method
or staining biofilms grown in microtitre plates. Inhibition
gainst S. aureus ATCC 29213 biofilm ranged from 89 to
8% at concentrations 1.5–0.047 mg/l using the MTT method
r 51.5–28.7% at the same concentrations but using crystal
iolet method (Fig. 3).
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Table 1
MIC and MBC values in vitro expressed in mg/l for all strains tested
I Vancomycin
MIC MBC MIC MBC
S. aureus ATCC 29213 0.01 3.1 1 >8
S. aureus ATCC 25923 0.005 1.5 1 8
S. epidermidis ATCC 12228 0.094 6.2 1 >8
S. epidermidis DSM 3269 0.003 0.37 2 4
E. faecalis ATCC 29212 0.19 12.5 4 >8
S. agalactiae ATCC 13813 0.04 1.5 1 4
L. monocytogenes NCTC 7973 0.002 0.37 1 >8
B. subtilis ATCC 6633 0.094 1.5 1 2
Fig. 2. In vitro percentages inhibition on S. epidermidis DSM3269 biofilm.
MTT and crystal violet (CV) methods. Values are the average of at least three
independent determinations. Coefficient of variation was less than 15%.
This discrepancy in data, depending on the method used
for staining biofilms, is due to different information derived
from these methods; MTT is a respiratory indicator and de-
tects killing activity by compound I, whereas crystal violet
staining, as an indicator of total attached biomass, shows re-
moval of bacteria by compound I. Compound I killed mi-
croorganisms in the biofilm rather than removing the biofilm
itself.
As far as we know, synthetic analogues of natural halo-
genated pyrroles have never been tested before as anti-biofilm
agents. Although the MIC and MBC values were low for all
tested strains, there was low activity against S. epidermidis
DSM 3269 and S. aureus ATCC 29213 biofilms, especially




planktonic form of these strains. Preformed biofilms were
inhibited at 15× MIC or more for S. epidermidis DSM 3269
and at 4× MIC or more for S. aureus ATCC 29213, although
there was good killing on the biofilms at the MBC for plank-
tonic S. epidermidis DSM 3269, 0.37 mg/l and at 1.5 mg/l for
S. aureus ATCC 29213, a concentration just below the MBC
(Figs. 2 and 3).
In conclusion, these data of the anti-bacterial activity of
compound I, specifically its activity against bacteria in a pro-
tective physiological form intrinsically refractory to antibi-
otics, such as biofilms, are worthy of interest. Anti-biofilm
activity should be considered an important factor in evaluat-
ing compounds as candidates for further development stages
in anti-microbial research [12]. For this reason, we think that
compound I might be a potential lead compound in the dis-
covery of new anti-Gram-positive and anti-biofilm agents.
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